Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
Holding PCVX?
Track your performance easily
PCVX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$53.83 - $121.06
Previous Close$87.72
Volume1.33M
Average Volume (3M)1.06M
Market Cap
$10.93B
Enterprise Value$8.78B
Total Cash (Recent Filing)$2.18B
Total Debt (Recent Filing)$27.96M
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Mar 03, 2025EPS Estimate
-$1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.68
Shares Outstanding124,636,546
10 Day Avg. Volume852,823
30 Day Avg. Volume1,061,474
Standard Deviation0.18
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.20
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-45.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-17.49
Forecast
1Y Price Target
$148.50Price Target Upside65.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Vaxcyte News
PremiumCompany Announcements
Vaxcyte, Inc. Navigates AI Risks Amidst Regulatory and Ethical Challenges
PremiumCompany Announcements
Vaxcyte Reports Progress and Strengthens Financial Position
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of the Phase 2 VAX-31 trial is ahead of initial timing guidance, showcasing the company's proactive approach in advancing its vaccine pipeline.
Competitive PositionVaxcyte's VAX-31 is significantly ahead in development compared to Pfizer's >30-valent vaccine, indicating a competitive edge in the pneumococcal vaccine market.
Market OpportunityThe recent ACIP recommendation to lower the age-based recommendation for PCVs to age ≥50 years significantly augments VAX-31's total addressable market.
Bears Say
Competitive PressurePFE's disclosure of its >30V PCV preclinical development effort is seen as a defensive move against PCVX's competitive threat.
Leadership ConcernsThe appointment of RFK Jr as Secretary of HHS initially created concerns about potential changes in vaccine policy that affected the stock.
Market ReactionPfizer's announcement of its >30-valent vaccine led to a sell-off of Vaxcyte's stock.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $53.83 and its highest was $121.06 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Currently, no data Available
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Mar 03, 2025 which is in 72 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on Nov 05, 2024. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$1.101 by $0.271.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -$1.12.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 124,636,540 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$0.83 in its last earnings report, beating expectations of -$1.101. Following the earnings report the stock price went down -3.245%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Among the largest hedge funds holding Vaxcyte, Inc.’s share is RA Capital Management. It holds Vaxcyte, Inc.’s shares valued at 993M.
---
Vaxcyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$148.50 (65.94% Upside)
$148.50 (65.94% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.07%
12-Months-Change
Fundamentals
Return on Equity
-21.06%
Trailing 12-Months
Asset Growth
137.94%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from most common and deadly diseases.
---
PCVX Company Deck
---
PCVX Earnings Call
Q4 2024
0:00 / 0:00
---
PCVX Stock 12 Month Forecast
Average Price Target
$148.50
▲(65.94% Upside)
Technical Analysis
Best Analysts Covering PCVX
1 Year
1 Year Success Rate
20/23 ratings generated profit
1 Year Average Return
+47.40%
reiterated a buy rating 2 months ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +47.40% per trade.
---